ArticleBiochemistry and biophysics reports2025
Investigating miR-30a's tumor suppressor role and its targets (MYBL2, TWF1, GALNT7, PFN2) as prognostic biomarkers in lung adenocarcinoma.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- METTL3-mediated mMolecular cancer · 2026Article
- PPIA regulates fatty acid and glutamine metabolism in lung adenocarcinoma based on multiomics prognostic model and experiment validation.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD), the most prevalent subtype of non-small cell lung cancer, is a significant cause of cancer-related mortality due to late-stage diagnoses and limited treatment options. Identifying effective biomarkers is crucial for improving prognosis and therapeutic strategies. miR-30a-5p has emerged as a potential tumor suppressor in LUAD, yet its exact role remains unclear. In this study, we analyzed three miRNA expression datasets from the GEO database and confirmed miR-30a downregulation in LUAD through TCGA and qRT-PCR validation. We identified MYBL2, TWF1, GALNT7, and PFN2 as oncogenic targets of miR-30a by integrating miRNA target predictions with gene expression data. Expression and survival analyses revealed an inverse relationship between miR-30a and these targets, with high expression levels correlating with poor patient outcomes. Functional enrichment analysis highlighted pathways in cell cycle regulation and actin cytoskeleton organization. Our findings underscore the significance of the miR-30a regulatory network in LUAD progression, positioning miR-30a and its targets as promising prognostic biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.